Dr. Niranjan Naik
Breast and GI Onco Surgery.
Director.

Dr. Niranjan Naik is a renowned senior surgical oncologist, presently the Director of Breast & Gastro-
Intestinal Onco-Surgery at Fortis Memorial Research Institute (FMRI), Gurgaon. He trained in
surgical oncology from the prestigious Institute Rotary Cancer Hospital (IRCH), All India Institute of
Medical Sciences (AIIMS), New Delhi. He has performed more than 12000 onco-surgical operations
since 1996. He has successfully done various complex onco-surgical operations including
laparoscopic and thoracoscopic procedures. He is also well versed in diagnostic and therapeutic
endoscopic procedures. He has been an invited faculty at various international and national
conferences. He has published numerous papers and research articles in journals of national and
international repute. He has also been a guide and mentor to DNB Surgical Oncology training
programme. He has a keen interest in advancements in oncology and was an investigator in a phase III
Clinical trial.

Work Experience:

Senior Consultant Surgical Oncologist: Dharamshila Narayana Super Specialty Hospital, Delhi-96.
Consultant Surgical Oncologist: At Mool Chand KR Hospital, Mata Chanan Devi Hospital,
Millennium Hospital, Pusa Road, Karol Bagh, Kailash Hospital, NOIDA.
Associate Consultant: Department of Surgical Oncology, Apollo Cancer Institute, Indraprastha Apollo
Hospitals, Sarita Vihar, New Delhi.
Senior Registrar: Department of Surgical Oncology, Apollo Cancer Institute, Indraprastha Apollo
Hospitals, Sarita Vihar, New Delhi.
Senior Resident: Department of Surgical Oncology, Institute Rotary Cancer Hospital (IRCH), AIIMS,
New Delhi.

Research Experience :

Symptomatic outcome after Laparoscopic Cholecystectomy. (Prospective study of 113 patients
undergoing laparoscopic cholecystectomy).

INVESIGATOR IN PHASE III CLINICAL TRIAL:Comparative PK, Efficacy, Safety and
Immunogenicity evaluation of Bmab-200 versus Herceptin®, both in combination with Docetaxel in
patients with Her2+ Metastatic Breast Cancer: A Double Blind, Randomised, Active Control, Parallel
assignment, Comparative Phase III Clinical Trial.

Short Title: Bioequivalence of Bmab-200 with Herceptin®

Protocol No: BM200-CT3-001-11 2013.
GUIDE IN DIPLOMATE OF NATIONAL BOARD (DNB) SURGICAL ONCOLOGY THESIS: The
role of {18F} FDG PET Scan in evaluation of clinic-pathological response of neo-adjuvant
chemotherapy in locally advanced breast cancer, Chief guide, 2014-2017

Qualification:

MBBS, MS (AIIMS), Onco-Surgery (IRCH, AIIMS), FIAGES